Darifenacin Tablet, Extended Release
Product Images NDC 52605-067

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 52605-067). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Polygen Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Darifenacin Fig01)

This appears to be a graph showing the percentage of patients with certain genotypes (EMs and PMs) who were administered doses of either 7.5mg or 15mg. The graph shows the percentage of patients who achieved a certain level of drug concentration over a certain amount of time after the dose. The time is measured in hours and ranges from 0 to 24 hours. The medication name, patient condition, or purpose of the graph is not available.*

FDA Label Image

Image (Darifenacin Fig02)

FDA Label Image

Image (Darifenacin Fig03)

FDA Label Image

Image (Darifenacin Fig04)

FDA Label Image

Image (Darifenacin Label 15mg 1000)

This is a medicine called "Darifenacin Extended-release tablets" containing 15mg of darifenacin. It is usually prescribed as one tablet daily or as directed by a physician. The container should be kept tightly closed and stored at 25°C, protected from light. Manufacturing and distribution is done by PolyGen Pharmaceuticals Inc.*

FDA Label Image

Image (Darifenacin Label 15mg 30)

This is a pharmaceutical label for Darifenacin extended-release tablets, containing 30 tablets, each with 17.858 mg of Darifenacin equivalent to provide 15 mg of Darifenacin, with a recommended dosage of one tablet daily or as directed by a physician. The pharmacist is advised to dispense patient information separately to each patient. The drug should be kept out of reach of children, and stored at 25°C (77°F) and protected from light. It is manufactured and distributed by PolyGen Pharmaceuticals Inc. in Edgewood, NY 11717, USA.*

FDA Label Image

Image (Darifenacin Label 15mg 90)

This is a description of a medication called Extended-release Lirdi Iomaton. Each tablet contains 15mg of darifenacin hydrobromide. The package insert should be consulted as directed by a physician. The medication should be kept away from children and stored at a temperature of 25°C (7°F) in a tightly closed container, protected from light. The medication is produced and distributed by PolyGen Pharmaceuticals Inc. It is available in a container of 90 tablets and is only available with a prescription.*

FDA Label Image

Image (Darifenacin Label 7 5mg 1000)

This is a description of Darifenacin Extended-release Tablets 7.5 mg, manufactured and distributed by PolyGen Pharmaceuticals Inc. Each tablet contains 8920 mg of darifenacin hydrobromide, providing 7.5mg of darifenacin. The recommended dosage is one tablet daily or as directed by a physician. The tablets come in a container holding 1000 tablets and should be stored at 25°C (77°F) and protected from light. The pharmacist needs to dispense the patient information separately to each patient. The container is not intended for household use.*

FDA Label Image

Image (Darifenacin Label 7 5mg 90)

This is a pharmaceutical label for Darifenacin Extended-release tablets with 90 tablets per bottle. Each tablet contains 8929 g of darfenacin hydrobromide equivalent to providing 7.5 mg darifenacin. It also mentions that the full prescribing information is included within the package. The drug is for prescription only, and it should be kept away from children while being stored at room temperature and protected from light. It is manufactured and distributed by Polygen Pharmaceuticals Inc. in Edgewood, NY.*

FDA Label Image

Image (Darifenacin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.